DeLand Treatment Solutions

Located in Columbia, MD, DeLand Treatment Solutions operates within the MD regulatory framework as a licensed addiction-treatment provider. The facility offers a continuum of care across multiple levels — Detox, IOP, MAT — which means it can, in principle, hold a patient across the arc of a typical treatment episode. Structural evaluation of this facility's clinical posture requires review of state licensing records, accreditation status, and payer-network contracts.

Care levels at DeLand Treatment Solutions

The facility offers a continuum of care across multiple levels — Detox, IOP, MAT — which means it can, in principle, hold a patient across the arc of a typical treatment episode. The practical question is whether it is genuinely strong at each level, or whether one level is the core business and the others are secondary. Operational prerequisite for admission: documented clinical assessment establishing medical necessity for the specific level of care DeLand Treatment Solutions provides. The ASAM Criteria 4e framework is the benchmark standard for this assessment and is referenced in most major payer medical-necessity documents.

Insurance and payment

Payment and insurance posture: DeLand Treatment Solutions accepts Medicaid — which is consequential because facilities that accept Medicaid tend to have the broadest patient populations and the most developed public-sector relationships, though reimbursement structures mean program intensity sometimes differs from commercial-focused centers. Pre-admission Verification of Benefits (VOB) documentation should include: specific plan product and network status, deductible status at time of admission, coinsurance rate applicable, prior authorization status and turnaround, and out-of-pocket accumulation. Under MHPAEA 2024 disclosure rules, plan-specific medical-necessity criteria must be available on request.

Before you call

Pre-admission due-diligence for DeLand Treatment Solutions: (1) ASAM 4e level-of-care documentation matching clinical assessment; (2) written Verification of Benefits specific to insurance product; (3) MAT policy documentation (particularly buprenorphine and methadone continuation protocols for opioid use disorder patients); (4) accreditation verification via CARF or Joint Commission provider-search tools; (5) state licensing status confirmed via MD behavioral-health regulator inspection records. The facility's documented pharmacotherapy offerings suggest MAT is available — confirm the specific medications and prescriber access during the admissions conversation.